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Abstract We have recently identified several novel ATP-
independent inhibitors that target the extracellular signal-
regulated kinase-2 (ERK2) protein and inhibit substrate
phosphorylation. To further characterize these compounds,
we describe the use of C. elegans as a model organism.
C. elegans is recognized as a versatile and cost effective
model for use in drug development. These studies take
advantage of the well characterized process of vulva
development and egg laying, which requires MPK-1, the
homolog to human ERK2. It is shown that treatment of
C. elegans eggs or larvae prior to vulva formation with a
previously identified lead compound (76) caused up to 50%
reduction in the number of eggs produced from the adult
worm. In contrast, compound 76 had no effect on egg
laying in young adult or adult worms with fully formed
vulva. The reduction in egg laying by the test compound
was not due to effects on C. elegans life span, general
toxicity, or non-specific stress. However, compound 76 did
show selective inhibition of phosphorylation of LIN-1, a
MPK-1 substrate essential for vulva precursor cell forma-
tion. Moreover, compound 76 inhibited cell fusion necessary
for vulva maturation and reduced the multivulva phenotype
in LET-60 (Ras) mutant worms that have constitutive
activation of MPK-1. These findings support the use of
C. elegans as a model organism to evaluate the selectivity





The extracellular signal-regulated kinase-1 and 2 (ERK1/2)
proteins belong to the mitogen-activated protein (MAP)
kinase superfamily and are important regulators of cell
growth, differentiation, inflammation and apoptosis (Pearson
et al. 2001). Activation of the ERK1/2 proteins occurs in
response to a variety of extracellular stimuli, which regulate
plasma membrane receptors and induce the sequential
activation of the well-defined pathway involving Ras
G-proteins, Raf kinases, and the MAP or ERK kinase-1
and 2 (MEK1/2) proteins. MEK1/2, the only known
ERK1/2 activators, regulate ERK proteins through dual-
phosphorylation of threonine (T) and tyrosine (Y) residues
within a TEY motif (Lewis et al. 1998). The activated ERK
proteins may phosphorylate and regulate the activity and
function of more than 70 different substrates, which include
transcription factors, other kinases, signaling proteins, and
structural proteins (Lewis et al. 1998; Pearson et al. 2001).
ERK1/2 activities are tightly regulated through a balance
between upstream MEK1/2 activation and inactivation by
phosphatases (Shapiro 2002). However, a shift in the
balance towards uncontrolled activation of the ERK1/2
signaling pathway is a hallmark of a variety of cancers
(Cohen 1999). Therefore, targeted inhibition of ERK
signaling is viewed as a potential approach for cancer
chemotherapy (Bollag et al. 2003; English and Cobb 2002;
Reuter et al. 2000; Sebolt-Leopold 2004; Thompson and
Lyons 2005; Wallace et al. 2005).
Given the diversity of ERK substrate proteins and the
importance of the ERK pathway in normal cell function,
one approach to the development of more effective and less
toxic chemotherapeutic agents involves the selective inhi-
bition of ERK activity that contributes to the disease state
while preserving ERK functions in the context of normal
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and biological approaches to identify and characterize small
molecular weight compounds that interact with ERK
proteins and interfere with substrate docking interactions
(Chen et al. 2006; Hancock et al. 2005). The initial set of
compounds was designed in silico to interact with a groove
that is situated between the common docking (CD) and ED
domain (Tanoue et al. 2001). The CD/ED docking domain
has been shown to regulate protein interactions between
ERK1/2 and the transcription factor ELK-1 (Zhang et al.
2003), and kinases such as p90RSK-1 (Dimitri et al. 2005).
Both ELK-1 and p90RSK-1 are important regulators of cell
proliferation in response to growth stimuli (Gille et al.
1995; Janknecht et al. 1993). In addition, ELK-1 and
p90RSK-1 contain two important docking sites termed the
D-domain and the FXFP motif or F-site, which are involved
in determining substrate interactions with ERK and other
MAP kinases (Fantz et al. 2001; Jacobs et al. 1999).
Computational methods for identifying low-molecular
weight ERK inhibitors take advantage of the 3-dimensional
structure of ERK2, which was solved by X-ray crystallog-
raphy in its unphosphorylated and phosphorylated forms
(Canagarajah et al. 1997; Zhang et al. 1994). Based on
these structures, work in our laboratories has identified
biologically active lead compounds with the potential to
target the CD/ED domain using in silico modeling of the
unphosphorylated (Hancock et al. 2005) or phosphorylated
ERK2 structure (Chen et al. 2006). Ongoing studies are
aimed at characterizing and improving the efficacy of these
lead compounds.
Caenorhabditis elegans (C. elegans) is recognized as a
powerful model organism for screening potential drug
compounds and validating drug efficiency prior to more
costly and time consuming in vivo studies (Artal-Sanz et al.
2006). C. elegans offers a variety of advantages in the drug
development process. For example, the genetics, biochem-
ical pathways, and developmental processes of C. elegans
have been well characterized and share many basic features
with higher organisms, including humans. In addition,
C. elegans studies are cost effective. The organisms are
easy to maintain in the laboratory and can be grown on agar
plates or liquid medium with E. coli as a food source.
Moreover, the reproductive life cycle of C. elegans is quite
short, taking 3.5 days from egg to fully mature adult. Thus,
developmental processes can be studied in a relatively short
period of time. Lastly, many C. elegans mutant strains are
readily available and can be used to explore protein
functions and mechanisms of drug action.
Many important signal transduction pathways found in
humans are conserved in C. elegans. For example, the
development of the vulva structure and subsequent egg
laying involves the highly conserved LET-23/LET-60/LIN-
45/MEK-2/MPK-1 signaling pathway, which is homologous
to the mammalian epidermal growth factor receptor
(EGFR)/Ras/Raf/MEK/ERK signaling pathway (Lackner
and Kim 1998). MPK-1 (also called Sur-1) shares approxi-
mately 80% homology with human ERK2 in the amino acid
sequence and is the only ERK ortholog in C. elegans (Wu
and Han 1994). As expected with such a high degree of
homology, the amino acid sequences that are important for
substrate recognition by the CD/ED docking domain are
identical in ERK2 and MPK-1. Activated MPK-1 phosphor-
ylates multiple downstream proteins including the LIN-1
ETS domain transcription factor (Jacobs et al. 1998). LIN-1
plays a critical role in the regulation of vulval cell fate
(Miley et al. 2004), which is consistent with the requirement
for the MPK-1 pathway in vulva formation and egg laying
(Lackner and Kim 1998). LIN-1 is a repressor of vulva cell
fate through its interactions with other transcription factors
(Tan et al. 1998). However, phosphorylation of LIN-1 by
MPK-1 may regulate vulva formation by relieving tran-
scription repression and promoting gene expression (Miley
et al. 2004; Tiensuu et al. 2005). As with many ERK
substrates, LIN-1 contains an F-motif and a D-domain that
are important determinants for interaction with MPK-1
(Miley et al. 2004). Importantly, evidence supports the
interactions of the D-domain of substrate proteins with the
CD/ED domain on ERK2 (Abramczyk et al. 2007).
The goal of these studies was to use C. elegans as a
model organism to further evaluate lead compounds that we
have identified to be promising inhibitors of ERK substrate
phosphorylation. Our studies indicate that small molecules
targeting MPK-1, the homolog to human ERK2, can inhibit
its interactions with LIN-1 substrates and disrupt the
development of the vulva and inhibit subsequent egg laying
capabilities. The findings suggest that C. elegans is a useful
model to evaluate the specificity and toxicity of promising
lead compounds that target ERK2 interactions with specific
substrate proteins and relevant physiological processes in a
whole organism.
Materials and methods
Reagents ERK docking domain inhibitors were identified
using computer aided drug design as previously described
(Hancock et al. 2005) and purchased from ChemBridge
(San Diego, CA). Compounds were dissolved in 100%
DMSO and stored at −20° in 25 mM stock solutions. The
maximal concentration of DMSO did not exceed 2% in the
working solutions used in experiments involving C. elegans.
LIN-1 and phospho-threonine MAPK/CDK substrate
antibodies were obtained from Santa Cruz Biotech (Santa
Cruz, CA) and Cell Signaling (Danvers, MA), respectively.
Antibodies against phosphorylated ERK MAP kinase and
α-tubulin were purchased from Sigma (St. Louis, MO).
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used in these studies included the wild-type N2, the
transgenic CL2070 (dvIs70), and BA17 (fem-1 (hc17))
strains. Additional strains included OH103 (mgIs21), SU93
(jcIs1) and MT2124 (let-60(n1046)) that were obtained
from the Caenorhabditis Genetic Center (University of
Minnesota, Minneapolis, MN). All strains were cultured in
nematode growth medium (NGM, 3 g/L NaCl, 17 g/L agar,
2.5 g/L peptone, 5 mg/L cholesterol, 25 mM KPO4 (pH 6),
1 mM MgSO4 and 1 mM CaCl2) with Escherichia coli
(E.coli) OP50 strain as the food source (Brenner 1974;
Stiernagle 2006). C. elegans strains were maintained at
20°C except the BA17 (fem-1 (hc17)) strain, which was
incubated at 25°C (Wilson et al. 2006).
Worm synchronization Two methods were used to obtain
age-synchronized eggs. In the first method, adult hermaph-
rodites were transferred onto fresh NGM plates and allowed
to lay eggs for 2–4 h and then removed. All the eggs
released in that time period have been shown to be well
synchronized (Epstein and Shakes 1995). In the second
approach, C. elegans were grown in liquid medium and
eggs were collected using the alkaline hypochloride method
(Sulston and Hodgkin 1988). Briefly, C. elegans were
added to a flask containing 200 mL of S Basal medium
(100 mM NaCl, 50 mM potassium phosphate (pH 6) and
5 mg/L cholesterol) and fed with concentrated E. coli
OP50. After shaking for 4 or 5 days at 20°C, the worms
were transferred to a 50 mL sterile conical centrifuge tube
and centrifuged at 1,000 rpm for 2 min (Stiernagle 2006).
The supernatant was removed and the worm pellet was
washed twice with M9 buffer (3 g/L KH2PO4, 6 g/L
Na2HPO4, 5 g/L NaCl and 1 mM MgSO4 7H2O) followed
by digestion with ten volumes of fresh hypochlorite
solution (1.0–1.3%sodiumhypochlorite,500mMpotassium
hydroxide). The samples were mixed by inversion, centri-
fuged, and the supernatant was removed. The digestion
procedure was repeated until the worms broke apart and the
carcass material was no longer visible (Sulston and Hodgkin
1988). The collected eggs were washed once with water,
three times with M9 buffer, and then transferred to 10 cm
NGM plates and kept at 20°C. The L1, L2, L3, L4 larvae
and young adult worms were then collected after 10, 24, 34,
46 and 58 h, respectively, based on previous studies
(Epstein and Shakes 1995). The stages of C. elegans
development were confirmed by microscopy.
Microscopy C. elegans were transferred into a 20–30 μL
drop of M9 buffer in the center of glass slide using a worm
pick and gently covered by a coverslip. Excess M9 buffer
was removed with filter paper in order to make sure that
the C. elegans did not move. The worms were observed
using a Nikon E800 Epi-fluorescence microscope (Image
Systems, Columbia, MD) and captured with a Hamamatsu
CCD camera. Worms were also observed and images
captured under light microscopy. Captured images were
processed and analyzed using IPlab software (Scanalytics,
Fairfax, VA).
Immunoblot analysis Various staged larvae were washed
three times using cold phosphate buffered saline (PBS) and
then lysed with 50 μL of tissue lysis buffer (TLB; 20 mM
Tris-base, pH 7.4, 137 mM NaCl, 2 mM EDTA, 1% Triton
X-100, 25 mM β-glycerophosphate, 10% glycerol, 0.2 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF), and 1 mM benzamidine) followed by
sonication for 15 one second pulses on ice. The lysates
were clarified by centrifugation at 20,000×g for 1 h and
added to 2X SDS-PAGE sample buffer at a 1:1 ratio.
Approximately 60 μg of total protein was separated by
SDS-PAGE, transferred to PVDF membrane (Perkin Elmer
Life Sciences; Boston, MA) and blocked for 1 h with 5%
nonfat dry milk in Tris-buffered saline (TBS-T; 50 mM
Tris-base, pH 7.4, 0.15 M NaCl, and 0.1% Tween-20).
Following incubation with primary antibodies in TBS-T
containing 1% BSA solution for 1 h, membranes were
washed several times in TBS-T solution and incubated with
HRP conjugated secondary antibodies (0.1 μg/ml). Mem-
branes were washed extensively with TBS-T and immuno-
reactivity was detected by enhanced chemiluminescence
(ECL; Amersham, Buckinghamshire, England).
Egg-laying assay C. elegans egg laying was evaluated
using previously described methods (Dempsey et al. 2005;
Trent et al. 1983). Briefly, synchronized worms at different
stages were incubated with the indicated test compounds on
NGM plates. Young adult worms were transferred onto fresh
plates (4 plates of 2 worms for each treatment). The number
of eggs released from each worm was counted on the 4th day
of the worm life cycle or as indicated in the text.
Survival assay Synchronized eggs from the BA17 (fem-1
(hc17)) temperature-sensitive strain were cultured on NGM
plates containing E. coli OP50 at 25°C. At this temperature,
the resulting adult worms are sterile and therefore can be
used to evaluate survival (Wilson et al. 2006). At L4 stage,
ninety BA17 larvae for each group were fed OP50 with and
without compound 76. The worms were transferred onto
fresh NGM plates containing food with and without 76
every other day and counted each day until all worms were
dead. Worms were scored as dead if they had no movement
response to touch stimulus.
Lethality assay L4 stage wild-type N2 larvae were trans-
ferred into a 24-well cell culture plate containing 1 mL of
S-medium with up to 500 μM of compound 76 and lethality
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Meel 2004). Compound 76 became insoluble at concen-
trations of 1,000 μM or greater. Briefly, worms were
incubated with the test compound at 20°C and the number
of dead worms was recorded after 24 h. Worms treated with
2% DMSO was used as a vehicle control. Each experiment
had eight worms per treatment and was repeated in three
independent studies.
Stress-response assay An evaluation of non-specific stress
responses due to the test compounds was performed using
the CL2070 strain. The CL2070 strain contains a GFP
reporter which is controlled by the heat shock promoter hsp-
16-2. The hsp-16-2 promoter is activated following expo-
sure to heat shock (35°C for 2 h) or oxidative stress (Strayer
et al. 2003). Synchronized L4 larvae were incubated with
OP50 containing 100–500 μM of compound 76 at 20°C for
24 h. The activation of the hsp-16-2 promoter was
measured by observing expression of GFP reporter using
fluorescence microscopy. Heat shock treated worms that
were allowed to recover at 20°C for 12 h were used as a
positive control.
Expression, purification and phosphorylation of LIN-1 The
plasmid pAT2 encoding the fusion protein glutathione-S-
transferase (GST):LIN-1 (C-terminal amino acids 241–441)
was kindly provided by Dr. Kerry Kornfeld (Washington
University School of Medicine, St. Louis, MI). BL-21
E. coli transformants were induced with 400 μM isopropyl
thiogalactoside (IPTG) for 4 h at 37°C and protein extracts
were obtained using BugBuster protein extract reagent
(Novagen) supplemented with protease inhibitors. The
GST:LIN-1 fusion protein was isolated by incubating with
Glutathione Sepharose 4B (GE Healthcare, Piscataway,
NJ), washed with excess 50 mM Tris (pH 8.0), and eluted
with 10 mM glutathione in 50 mM Tris-HCl (pH 8.0). The
glutathione was removed by dialysis for 2 h at 4°C against
25 mM Tris-HCl (pH 7.5), 5% Glycerol, 0.2 M NaCl, and
0.1% 2-mercaptoethanol. Samples were concentrated using
an Amicon Ultra-4 Centrifugal Filter Unit, 10 kDa cutoff
(Sigma) and aliquots were stored at −80°C. Purified GST:
LIN-1 was incubated in the absence or presence of 10 ng
active p42 ERK2 MAP kinase (New England Biolabs,
Beverly, MA) in MAP kinase reaction buffer (50 mM Tris-
HCl, 10 mM MgCl2, 2 mM DTT, 1 mM EGTA, 0.01% Brij
35, pH 7.5) supplemented with 200 μM ATP at 30°C for
30 min. In some cases, the active p42 MAP kinase was
preincubated with the test compound at room temperature
for 15~20 min prior to adding the GST:LIN-1 substrate
with test compounds. Following the kinase reaction GST-
LIN-1 was re-isolated with Glutathione Sepharose 4B and
incubated in the absence or presence of 2.5 μg λ-
phosphatase (New England Biolabs) in λ-phosphatase
reaction buffer (50 mM Tris-HCl, 100 mM NaCl, 2 mM
MgCl2, 2 mM DTT, 0.1 mM EGTA, 0.01% Brij 35,
pH 7.5). LIN-1 phosphorylation was also examined in the
presence of active CDK1 (New England Biolabs). Histone
H1 (Sigma) was used as a control substrate for CDK1
activity. The kinase or phosphatase reactions were stopped
by addition of 2× SDS-PAGE sample buffer. Phosphoryla-
tion of LIN-1 or histone H1 was examined by immuno-
blotting with the phospho-threonine MAPK/CDK substrate
antibody.
Vulva formation Following treatment in the presence or
absence of the test compound, vulva structure and cells
were observed by light and fluorescence microscopy in
wild type N2, OH103, and SU93 strains. The OH103 strain
expresses the lin-11 promoter driving GFP expression in
vulA, vulB1, vulB2, vulC and vulD cells and was used to
show cell fate specification (Hobert et al. 1998). The SU93
strain, AJM-1:GFP, contains the apical junction-associated
protein, AJM-1 (formerly JAM-1), fused to GFP to monitor
fusion of the symmetric halves of the vulva in a single
organ (Hurd and Kemphues 2003; Michaux et al. 2001;
Mohler et al. 2002). Images of vulval cell fusion were
recorded and the percentage of worms containing cell
fusion was calculated in control and treatment conditions.
Cell fusion defects in worms were counted if a gap between
the tips of the cellular extensions from the anterior and
posterior vulA-D cells was observed. At least 20 worms
were examined under each condition.
Statistical analysis Comparisons between control and treat-
ment groups wereperformed with two population t-test using
Origin 6.0 software (Microcal Software, Northampton,
MA). Statistical significance was indicated if p values were
less than 0.05. The standard error of the mean is shown in
the figures.
Results
MPK-1 activation during the C. elegans life cycle MPK-1
activity plays a key role in the development of the vulva
structure in C. elegans (Lackner et al. 1994; Wu and Han
1994). MPK-1 activation was examined during the devel-
opment of C. elegans by evaluating the levels of phosphor-
ylated MPK-1 protein in whole organism protein extracts
using a phospho-specific antibody. Phosphorylated MPK-1
was first observed in L2 stage and reached peak levels
during L3 stage (Fig. 1). Subsequently, phosphorylated
MPK-1 levels decreased in L4 stage and in young adult
worms (Fig. 1). These results are in agreement with
previous findings demonstrating that MPK-1 activation is
required for vulva development (Lackner et al. 1994). Thus,
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development and egg laying as a model for evaluating test
compounds that are proposed to inhibit ERK interactions
with substrate proteins.
Effect of MPK-1 inhibition on egg laying In the first set of
studies to characterize the model, we established the time
course for egg laying in controls and worms treated with a
lead ERK inhibitor compound. Our studies focused on a
putative ERK inhibitor, referred to as compound 76, that we
have previously reported to inhibit ERK substrate phos-
phorylation in cultured mammalian cells (Hancock et al.
2005). Synchronized eggs were isolated and grown in the
absence or presence of 76 or the MEK inhibitor, U0126,
added to the OP50 food source. When worms reached
adulthood (day 3), the number of eggs produced were
counted each day for the next 5 days (days 3 through 8).
Untreated worms showed peak egg production at day 4
(Fig. 2A), which is consistent with previous studies (Byerly
et al. 1976). Worms treated with 76 produced 50% fewer
eggs at day 4 compared to untreated controls (Fig. 2A). As
a control, treatment with U0126 also inhibited the number
of eggs produced at day 4 and is consistent with the
requirement for MPK-1 in this process.
Fig. 1 Activation of MPK-1 during the C. elegans life cycle.
Synchronized eggs were cultured as described in the methods and
worms were collected at L1, L2, L3, L4 larvae and young adult stages.
(A) Total protein was extracted and immunoblotted for active
phosphorylated MPK-1 (pMPK-1) using a phospho-ERK MAP kinase
antibody and α-tubulin as the protein loading control. (B) Quantifi-
cation of the ratio of pMPK-1 to α-tubulin as measured by
densitometry scanning
Fig. 2 Effects of ERK docking domain inhibitors on C. elegans egg
laying. (A) Synchronized eggs were grown on NGM plates in the
absence (Control) or presence of U0126 (50 μM) or compound 76
(500 μM). The number of eggs released was recorded from the 3rd
day to the 8th day of the worm life cycle. Eggs from eight worms in
each group were counted. (B) Synchronized eggs, L3, L4, young adult
(YA) or adult worms (A) were incubated with 100, 250 or 500 μMo f
compound 76 and then the number of eggs laid was calculated during
the 4th day of the worm life cycle. (C) Synchronized L4 larvae were
treated with the indicated compounds (500 μM) whose structures were
identified by in silico modeling to be similar to 76 and the number of
eggs laid was calculated during the 4th day of the worm life cycle. (D)
Chemical structures for 76 and structurally similar compounds 99–108
b
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mental stage in which 76 affected egg laying behavior.
Synchronized eggs, L3, L4, young adult, or adult worms
were incubated with OP50 supplemented with different
concentrations of 76 and the number of eggs per worm was
determined on day 4 of the C. elegans life cycle as
described above. Egg laying was inhibited in a dose
dependent manner when compounds were added to eggs,
L3, or L4 larvae (Fig. 2B). In contrast, treatment of young
adult or adult worms with compound 76 had no affect on
the number of eggs laid by these worms. These data are
consistent with the requirement for MPK-1 in vulva
development and that inhibition of MPK-1 functions prior
to vulva formation influences egg laying capacity.
To evaluate additional compounds with structural simi-
larities to 76, a computer aided drug design similarity
search was performed and ten new compounds were
obtained from commercial sources. The similarity search
was based on MAC_BITS chemical fingerprints quantified
using the Tanimoto Index as implemented in the program
MOE (Chemical Computing Group) and as previously
described (Macias et al. 2005). These compounds were
evaluated for inhibition of egg laying with four compounds
(100, 101, 102, and 108) causing significant inhibition of
egg laying similar to 76 (Fig. 2C). The structures of 76 and
the similarity search compounds are shown in Fig. 2D.
These studies identify a class of compounds that appear to
inhibit C. elegans egg laying by targeting MPK-1 function.
It is anticipated that members of this class of compounds
will be amenable to lead optimization studies with the goal
of maximizing the affinity and specificity of the compounds
as inhibitors of ERK.
Evaluation of non-specific effects and general toxicity of
compound 76 The effective concentration of 76 used in the
C. elegans egg laying studies shown in Fig. 2 was relatively
high (250–500 μM) and approximately 4–6 times higher
than effective concentrations used in previous studies with
cultured mammalian cells (Hancock et al. 2005). In order to
exclude the possibility that inhibition of egg laying
behavior is caused by non-specific toxicity due to high
concentrations of test compound, we evaluated the effect of
76 on the life span of C. elegans. As shown in Fig. 3, the
presence of 500 μM compound 76 had no significant effect
on the average life span as compared to untreated worms.
The potential for toxicity of 76 was further assessed
using a lethality assay where C. elegans were exposed to
increasing concentration of test compound. Compound 76
at concentrations of up to 500 μM had no effect on lethality
after 1 day exposure (data not shown). Increasing the
concentrations of 76 to 1,000, 1,500, 2,000 μM were lethal
to approximately 0%, 10%, 25% of the worms, respectively
(data not shown). However, 76 became insoluble at these
doses so the effective lethal dose can not be accurately
determined. Nonetheless, these data suggest that concen-
trations of 76 that inhibit egg laying are not due to general
lethality of the compound or effects on C. elegans life span.
Additional evidence for 76 effects on non-specific stress
responses was evaluated using the transgenic strain CL2070
containing the HSP-16-2 promoter driving GFP expression.
The HSP-16-2 promoter responds to general stress stimuli,
which can be evaluated by the degree of GFP expression.
As shown in Fig. 4, the dose of 76 that inhibited egg laying
had no effect on HSP-16-2 dependent GFP expression.
These data further support the findings that the effects of 76
on egg laying were not due to a non-specific stress response
or toxicity to the organism.
Compound 76 inhibition of egg laying involves targeting
MPK-1 mediated LIN-1 phosphorylation MPK-1 regulation
of vulva formation involves phosphorylation of the tran-
scription factor LIN-1, which is homologous to human
Elk-1 (Jacobs et al. 1998; Miley et al. 2004). LIN-1, which
contains a D-domain that may interact with the CD/ED
domain on ERK2, is an important cell fate regulator of
vulva cells (Miley et al. 2004). To test whether 76 targets
MPK-1, the C-terminus of LIN-1, which contains the D-
domain and phosphorylation sites was purified as a GST
fusion protein and incubated with activated ERK2 in the
presence or absence of 76. Active ERK2 enhanced the
phosphorylation of LIN-1 as detected with a phospho-
threonine MAP kinase substrate specific antibody
(Fig. 5A). The ERK-mediated LIN-1 phosphorylation,
(pT)LIN-1, was inhibited in the presence of 76 or following
phosphatase treatment (Fig. 5A). Treatment with compound
76 had no effect on the level of phosphorylated ERK,
Fig. 3 Compound 76 does not affect C. elegans life span. At L4
stage, the BA17 (fem-1 (hc17)) C. elegans strain was exposed to 76
(500 μM) or DMSO as a control. Three plates containing 30 worms
each were used for each condition. Worms were transferred onto new
plates every other day in the presence or absence of compound 76.
The number of live animals was recorded each day for 20 days
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phosphorylation were due to disruption of protein-protein
interactions. Activated ERK2 caused a dramatic retardation
of LIN-1 gel mobility (Fig. 5A), which is due to phos-
phorylation as observed previously (Tan et al. 1998). This
was confirmed by demonstrating that phosphatase treatment
could restore the faster migrating form of LIN-1 (Fig. 5A).
Compound 76 restored some of the faster migrating forms
of LIN-1 and could be due to partial inhibition of all ERK-
mediated LIN-1 phosphorylation sites or selective inhibi-
tionofsomesites(Fig.5A). To further confirm the specificity
of the ERK-mediated LIN-1 phosphorylation, LIN-1 was
incubated with activated cyclin dependent kinase 1 (CDK1
or Cdc2), another proline directed serine/threonine kinase.
Again, LIN-1 phosphorylation was evaluated by the
phospho-threonine (pT) specific antibody that recognizes
proline directed phosphorylations mediated by CDK or MAP
kinase proteins. No phosphorylation of LIN-1 by CDK1 was
observed (Fig. 5B). Importantly, CDK1-mediated threonine
phosphorylation of a histone substrate, (pT) histone, was
unaffected by 76 (Fig. 5B). These findings help support the
specificity for 76 in the inhibition of MPK-1 mediated
phosphorylation of LIN-1 but not general inhibition of
proline directed phosphorylation events.
Effect of compound 76 on vulva formation Having estab-
lished that 76 may affect egg laying by inhibiting MPK-1
mediated phosphorylation of the LIN-1 substrate involved
in vulva formation, the next series of experiments examined
structural changes in the vulva following treatment with 76.
The overall vulva structure as viewed by light microscopy
did not appear to change in L4 larvae treated with or
without 76 (Fig. 6A and B). The first set of experiments
took advantage of transgenic strains, OH103 (lin-11::GFP)
and SU93 (ajm-1::GFP), expressing GFP driven by a
promoter that is activated in vulva or uterine cells (see
Methods for description of strains). In these studies, eggs
from the OH103 strain were treated with and without 76
and GFP patterns in L3 or L4 larvae were examined. As
shown in Fig. 6C and D, GFP expression could be observed
in vulva precursor cells. However, no distinct changes in
vulva cell patterns were observed in controls or 76 treated
worms and control and treated cells contained a similar
number of GFP positive cells, respectively (Fig. 6G). Next,
eggs from the transgenic strain SU93, which express the
apical junction-associated AJM-1-GFP chimeric protein
and can evaluate vulva cell fusion during L4 stage (Gupta
et al. 2003; Hurd and Kemphues 2003; Inoue et al. 2002),
were treated with and without 76. As compared to controls,
treatment with 76 caused an apparent defect in vulva cell
fusion as shown by the 2 fold inhibition of the joining of
the two symmetric halves of homologous cells that will
form the functional vulva structure (Fig. 6E, F and H).
These findings indicate that while 76 does not significantly
influence the generation of vulva precursor cell types, it does
inhibit the ability for these cells to form a functional vulva.
Effects of 76 on the LET-60 multivulval phenotype Con-
stitutively active LET-60 is the C. elegans ortholog to the
human RAS protein that is mutated in a variety of human
cancers. Active LET-60 causes constitutive activation of the
MPK-1 pathway and results in the generation of a multi-
vulval (Muv) phenotype (Beitel et al. 1990). The Muv
phenotype of this mutant strain includes one functional
vulva and one or more pseudovulvae, which present
themselves as round or other asymmetric invaginations
(Fig. 7A). Inhibition of MPK-1 pathway with the MEK
inhibitor U0126 has been shown to reduce the Muv
phenotype in LET-60 expressing worms (Reiner et al.
2008). Therefore, this transgenic strain is a useful tool for
characterizing the efficiency of putative ERK pathway
inhibitors on vulva formation. The Muv phenotype was
found in 92.3% of mutant worms and the average number
of vulvae was 2.75 in the DMSO vehicle-treated controls
Fig. 4 Compound 76 does not induce Hsp-16 stress response.
Fluorescent images of L4 larvae from the CL2070 strain containing
a GFP reporter, which is controlled by heat shock promoter hsp-16-2,
following 24 h treatment with 2% DMSO as a control (A) or 500 μM
of compound 76 (B). As a positive control worms were heat shocked
at 35°C for 2 h followed by a 12 h recovery at 20°C (C). Fluorescent
images were taken using the same exposure time and are representa-
tive of at least three independent experiments
Using Caenorhabditis elegans as a model organism 87(Fig. 7A, D and E). In contrast, only 23% of the worms
incubated with 76 showed the Muv phenotype and the
average vulva number per worm was reduced to 1.32
(Fig. 7B, D, and E). As a control and in agreement with
previous reports (Reiner et al. 2008), the MEK inhibitor,
U0126, also inhibited the Muv phenotype in LET-60
mutant worms (Fig. 7C, D, and E).
Discussion
The ERK1/2 signaling pathway represents a key target for
the development of clinically effective anticancer agents.
To date, several inhibitors of upstream ERK regulators
including tyrosine kinase receptors, Ras, Raf, and MEK
proteins have been developed with limited clinical success
Fig. 6 Effect of compound 76 on vulva formation. Gross structural
morphology of vulva in wild-type N2 strain treated in the absence (A)
or presence (B) of 500 μM compound 76. Organization and fusion of
vulva cells was observed using the OH103 strain, which expresses
GFP driven by the lin-11 promoter in uterine (ut) and vulva (vul) cells,
and the SU93 strain, which expresses the AMJ-1-GFP chimeric
protein during vulva cell fusion. GFP expression in untreated (C and
E) and 76 treated (D and F) worms was examined by fluorescence
microscopy in the OH103 (C and D) or SU93 (E and f) strains. g
Quantification of the number of GFP positive vulval (Vul) precursor
cells in the absence or presence of 76 in the OH103 strain. (H)
Quantification of percentage of vulva in SU93 worms showing fusion
of the two symmetric halves in the absence or presence of compound
76. 20 worms were analyzed under each condition
Fig. 5 Inhibition of ERK-mediated LIN-1 phosphorylation by
compound 76.( A) GST tagged LIN-1 protein was incubated with
active ERK2 MAP kinase in the absence or presence of 76 (100 μM)
or λ-phosphatase (PPase). The proteins were immunoblotted with
antibodies against LIN-1, phospho-threonine MAPK/CDK substrates
(pT), total LIN-1, and phosphorylated MAP kinase (pERK) in the top,
middle, and lower panels, respectively. (B) Effect of compound 76 on
LIN-1 and histone phosphorylation by CDK1. Histone and GST-LIN-
1 proteins were incubated with CDK1 (CDC2) kinase in the absence
or presence of 100 μM compound 76. The proteins were detected with
antibodies against CDC2, phospho-threonine MAPK/CDK substrates
(Histone and LIN-1), and total LIN-1 in the top, middle, and bottom
panels, respectively
88 F. Chen et al.(Bollag et al. 2003; English and Cobb 2002; Kohno and
Pouyssegur 2003; Kohno and Pouyssegur 2006; Sebolt-
Leopold 2004; Wallace et al. 2005). Thus, new approaches
for inhibiting ERK signaling events and cell proliferation
are needed. The ubiquitous nature of ERK1/2 expression in
all cell types presents a challenge for the development of
ERK pathway inhibitors that are selective for ERK and its
functions in promoting cancer cell growth and survival
while preserving ERK actions in normal cells. We have
recently described an approach using computational and
biological methods to identify ERK inhibitors that have the
potential to be substrate selective such that ERK activation
is intact but the ability for ERK to interact with and regulate
substrates involved in cell proliferation is inhibited (Chen
et al. 2006; Hancock et al. 2005). To our knowledge, these
studies are the only ones to report the identification of ERK
inhibitors that act independent of ATP binding and have the
potential to be substrate selective. Other studies have
recently described the identification of pyrazolylpyrrole-
based compounds that inhibit ERK proteins by competing
with ATP binding (Aronov et al. 2007; Ohori et al. 2005).
Our findings support the use of C. elegans as a model
organism for identifying, screening, and characterizing
potential lead pharmacological agents that target specific
signaling proteins. We have applied this model to evaluate
the specificity and toxicity of a promising lead compound
(76) that is predicted to target protein interactions with an
ERK docking domain, referred to as the common docking
(CD) domain. The C. elegans model is recognized to offer
many advantages in the drug discovery and development
process. In the context of the current studies, the ERK
signaling process in C. elegans and its involvement with
vulva formation and egg laying is well-characterized.
Others have also used C. elegans models to evaluate
inhibitors of Ras proteins, which are commonly mutated
in human cancers (Reiner et al. 2008). This report took
advantage of the Ras-induced multivulval phenotype for
analysis of inhibitory compounds similar to the current
studies (Fig. 7). While the possibility exists that lead
compound 76 is reducing egg laying by affecting other
targets in the Ras-Raf-MEK-ERK pathway, our previous
reports demonstrate that the inhibitory effects of 76 are at
the level of ERK interactions with downstream substrates,
such as p90RSK-1 or Elk-1, and does not interfere with
ERK interactions with upstream regulatory kinases, such as
MEK1/2 (Hancock et al. 2005). This is consistent with
Fig. 7 Compound 76 reduces
Ras induced multivulval (Muv)
phenotype. Eggs from the
Let-60 (n1046gf) strain
containing the ortholog to
human Ras mutations were
treated in the absence or
presence of 500 μM of com-
pound 76 or 50 μM of the MEK
inhibitor U0126. Images show
control (A), 76 treated (B), or
U0126 treated (C) L4 stage
worms. The boxed areas in the
insets of each panel show the
vulva and pseudovulvae marked
by the black and white arrows,
respectively. The graphs show
the percentage of worms con-
taining the Muv phenotype (D)
and the average number of
vulvae per worm (E) under each
condition. The microscopic
images in panels A, B and C
were taken at 100× and the
insets were magnified 600×.
Fifteen to twenty worms were
analyzed under each condition
Using Caenorhabditis elegans as a model organism 89other reports that demonstrate that the CD domain is more
important for ERK interactions with substrates such as
p90RSK-1 but not for interactions with MEK proteins
(Robinson et al. 2002).
One of the concerns of using the C. elegans model for
drug discovery is the determination of the effective dose for
a lead compound. The test compounds used in these studies
were provided to the worms through the E. coli food
source. Thus, the effective concentration absorbed through
the intestinal lumen is not known. C. elegans also has an
outer exoskeleton or cuticle that is synthesized and shed
during each larvae stage and may provide protection from
environmental chemicals (Page and Johnstone 2007). The
presence of the exoskeleton could likely interfere with
the absorbance of test compounds not ingested through the
food source. Regardless, the concentrations of 76 used in
these studies did not appear to induce general toxicity or
reduce the worm life span.
In addition to affecting vulva formation, inhibition of
MPK-1 may affect other processes, such as germline
development during meiosis, that impact egg laying behavior
(Lee et al. 2007). In C. elegans hermaphrodites, spermato-
genesis occurs transiently during L3 and L4 larval stages
whereas oogenesis occurs from L4 until adulthood (Lee
et al. 2007). In male worms, spermatogenesis occurs from
L3 until adulthood (Lee et al. 2007). Thus, it is possible that
inhibition of MPK-1 with 76 in larval stages up to and
including L4 could affect germline maturation, subsequent
fertilization, and ultimately egg laying. However, treatment
of young adult worms with 76 did not affect egg laying
behavior indicating that oocyte maturation at this time of the
life cycle and subsequent fertilization by mature sperm was
not likely affected (Fig. 2).
An important finding of these studies demonstrated that
76 inhibited ERK-mediated LIN-1 phosphorylation (Fig. 5).
As LIN-1 is an important regulator of precursor vulva cell
fate (Tiensuu et al. 2005). Reduced LIN-1 phosphorylation
and activity could explain the observed defects in vulva
formation (Fig. 6). LIN-1 contains a D-domain (also called
DEJL site or docking site for ERK or JNK, LXL residues)
and an F-site (also called a DEF motif or docking site for
ERK, FXFP residues) (Fantz et al. 2001). These residues
make contacts with distinct docking domains on ERK
proteins to confer substrate specificity and it is thought that
these domains play a role in determining what residues will
be phosphorylated (Fantz et al. 2001). The CD and ED
domains, which correspond to residues D316/D319 and
T157/T158, respectively, on ERK2 are the best charac-
terized regions involved in substrate interactions (Tanoue
et al. 2000). The CD/ED docking domain residues have
been shown to coordinate protein interactions between
ERK and substrates containing the D-domain, which
include the dual specificity phosphatase MKP-3 (Zhang
et al. 2003), ELK-1 (Abramczyk et al. 2007; Fantz et al.
2001), RSK-1 (Dimitri et al. 2005), caspase-9 (Martin et al.
2008). Another ERK2 docking pocket consisting of
residues L198, L232, L235, and Y261 may mediate ERK2
interactions with the F-site on substrates (Dimitri et al.
2005; Sheridan et al. 2008). The fact that LIN-1 contains
both a D-domain and an F-site may account for the partial
effects of 76 on inhibiting ERK-mediated phosphorylation
(Fig. 5). While the findings suggest that 76 may disrupt
ERK interactions with LIN-1 by targeting the region around
the CD/ED domain, the exact nature of the binding inter-
actions between 76 and ERK have yet to be determined.
Our findings indicate that inhibition of egg laying may
be a result of the improper formation or assembly of vulva
cells (Fig. 6). These findings suggest that the fusion of
homologous cells from each half of the vulva is inhibited in
the presence of 76. One explanation for this observation is
that inhibition of MPK-1 mediated LIN-1 phosphorylation
by 76 prevents expression of LIN-39, a transcription factor
that regulates the process of vulva cell fusion (Wagmaister
et al. 2006). Alternatively, 76 may directly inhibit phos-
phorylation of LIN-39, which has been demonstrated to be
a substrate of MPK-1 in vitro (Wagmaister et al. 2006).
Another consideration is that 76 may affect other signaling
pathways, such as the Wnt pathway, which regulates vulva
development potentially through regulation of LIN-39.
Nonetheless, future examination of these potential inter-
actions along with other signaling events in the C. elegans
model will help further define the mechanisms of action for
novel kinase targeted compounds.
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